medigraphic.com

2004, Number 4

<< Back Next >>

Arch Cardiol Mex 2004; 74 (4)

Usefulness of trimetazidine in ischemia-reperfusion lesion. Experimental study in myocardial stunning model.

Morillas P, Hernández A, Pallarés V, Bertomeu V, Roldán FJ, Capdevilla C, Azorín I, Aguilar A, Portolés M, Cosín J

Language: Spanish
References: 30
Page: 262-270
PDF size: 81.71 Kb.


ABSTRACT

Objective: The aim of this study is to evaluate the effect of trimetazidine (TMZ) on myocardial systolic dysfunction resulting from an isolated episode of induced coronary ischemia. Methods: In a double-blinded randomized design we studied 13 mongrel anesthetized dogs of either sex (6 of them treated with oral TMZ previously). The anterior descending coronary artery was totally occluded during 15 minutes followed by 60 minutes of reperfusion. Global and regional cardiac variables were recorded in control and ischemic areas. Results: There were no significant differences between TMZ and placebo series with respect to global cardiac function variables. Both series showed no significant variations in global variables during the ischemia-reperfusion process. The shortening fraction in the ischemic area fell significantly during the ischemic period in both TMZ and placebo series reaching dyskinetic values. Myocardial contractility dysfunction persisted after 60 minutes of reperfusion in both series with no significant differences (41% vs 50% placebo). Conclusions: Contrary to shorter and repeated occlusion periods, myocardial contractility recovery after a complete episode of ischemia did not show significant differences between TMZ-treated and placebo series.


REFERENCES

  1. Jackson G: Haemodynamic and metabolic agents in the treatment of stable angina: publication review. Coron Artery Dis 2001; 12: S22-S24.

  2. Lopaschuk GD: Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease. Eur Heart J 1999; 1: 032-039.

  3. Bolli R: Myocardial “Stunning” in man. Circulation 1992; 86: 1671-1691.

  4. Kloner RA, Jennings RB: Consequences of brief ischemia: stunning, preconditioning and their clinical implication: part 1. Circulation 2001; 104(24): 2981-2989.

  5. Gao WD, Atar D, Liy Y, Pérez NG, Murphy AM, Marban E: Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997; 80: 393-399.

  6. Pallarés V, Cosín J, Hernándiz A, Pomar F, Portolés M: El aturdimiento miocárdico en la isquemia. Clínica Cardiovascular 1995; 13: 37-48.

  7. Braunwald E, Kloner RA: The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149.

  8. Marsch SC, Dalmas S, Philbin DM, Ryder WA, Foex P: Myocardial ischemia and reperfusion are associated with an increased stiffness of remote non ischemic myocardium. Anesth Analg 1996; 82: 695-701.

  9. Sharma G, Varley K, Kim S, Barwinsky J, Cohen M, Dhalia N: Alterations in energy metabolism and ultraestructure upon reperfusion of the ischemic myocardium after coronary occlusion. Am J Cardiol 1975; 36: 234-243.

  10. Nayler WG: El miocardio isquémico y los antagonistas del calcio. En: Opie L, ed. Protección miocárdica mediante antagonistas del calcio. Barcelona: Ediciones médicas, 1998; 46-61.

  11. Rivera JM, Cosín J, Hernándiz A, Andrés F, Solaz J: Estudio de la acción cardioprotectora del propranolol durante las isquemias transitorias de duración breve. Rev Lat Cardiol 1992; 13: 8-13.

  12. Kalaycioglu S, Sinci V, Imren Y, Oz E: Metoprolol prevents ischemia-reperfusion injury by reducing lipid peroxidation. Jpn Circ J 1999; 63: 718-721.

  13. Bolling SF, Bies LE, Bove HL, Gallagher KP: Augmenting intracellular adenosine improves myocardial recovery. J Thorac Cardiovasc Surg 1990; 99: 469-474.

  14. Pichardo J, Chávez R, Bravo C, Zazueta C, Chávez E: Protección por Ketorolaco en el daño producido por isquemia y reperfusión miocárdica. Arch Inst Cardiol Mex 1994; 64: 325-330.

  15. Ferrari R, Pepi P, Ferrari F, Nesta F, Benigno M, Visioli O: Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol 1998; 82: 2K-13K.

  16. Ruffolo RR, Feuerstein GZ: Pharmacology of carvedilol: rationale for use in hypertension coronary artery disease and congestive heart failure. Cardiovasc Drugs Ther 1997; 11: 247-256.

  17. Hernádiz A, Pallarés V, Cosín A, Andrés F, Capdevilla C, Sanz M: Efectos de L-carnitina sobre la función regional del miocardio aturdido por isquemias de muy breve duración. Rev Esp Cardiol 1997; 50(9): 650-657.

  18. Artigou JY, Chamiot JC, Bonnefont-Rousselot D, Salloum J, Grosgogeat Y: Le traitement antioxydant dans l´ischemie reperfusion myocardique. Arch Mal Coeur 1993; 86 (IV): 105-109.

  19. Kantor P, Lucien A, Kozack R, Lopaschuk G: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-Ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-588.

  20. Cross H: Trimetazidine for stable angina pectoris. Exp Op Pharmacother 2001; 2(5): 857-875.

  21. Vedrinne C, Sebbag L, Arvieux C, Cannet E, Forrat R, Hadour C, et al: Effect of trimetazidine on postischemic regional myocardial stunning in the halothane-anesthetized dog. J Cardiovasc Pharmacol 1996; 28: 500-506.

  22. Rahman F, Toshima Y, Kohno H, Kinoshita K, Tokunaga K: The protective effects of trimetazidine on normothermic ischemic myocardium in rats. Jpn J Surg 1989; 19 (3): 346-350.

  23. Morillas P, Hernándiz A, Pallarés V, Capdevilla C, Andrés L, Bertomeu V, et al: ¿Es eficaz la trimetazidina en el aturdimiento miocárdico? Estudio experimental en un modelo canino. Rev Lat Cardiol 2001; 22: 234-241.

  24. Morillas P: Citoprotección miocárdica: Efecto de la trimetazidina en la isquemia miocárdica. Facultad de Medicina de Valencia. 2002 (Tesis).

  25. Morillas P, Hernándiz A, Pallarés V, Bertomeu V, Azorín A, Aguilar A, et al: Mitochondrial changes induced by trimetazidine (abstract 42). En: 12th International Congress on Cardiovascular Pharmacotherapy. Barcelona 2003.

  26. EMIP-FR Study Group. Effect of 48 h intravenous trimetazidine on short-and-long-term outcomes of patients with acute myocardial infarction with and without thrombolytic theraphy. A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Eur Heart J 2000; 18: 1537-46.

  27. Camilleri JP: Effects of trimetazidine on experimental reperfused infarction in the rat. Eur Heart J 1988; 9 (Suppl 1): 217.

  28. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P, et al: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-288.

  29. Michaelides AP, Vyssoulis K, Dimopoulos K: Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14.

  30. Lu C, Dabrowski P, Fragasso G, Chierchia SL: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.




2020     |     www.medigraphic.com